
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2498868/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis, 2017, 11, 3-25.	0.6	1,547
2	Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointestinal Endoscopy, 2004, 60, 505-512.	0.5	1,326
3	European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, 982-1018.	0.6	679
4	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 30-35.	2.4	316
5	Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2011, 5, 484-498.	0.6	93
6	Neuropeptide S Receptor 1 Gene Polymorphism Is Associated With Susceptibility to Inflammatory Bowel Disease. Gastroenterology, 2007, 133, 808-817.	0.6	87
7	Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflammatory Bowel Diseases, 2007, 13, 896-902.	0.9	84
8	Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2014, 46, 969-973.	0.4	78
9	Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut, 2016, 65, 1119-1125.	6.1	74
10	Abdominal bowel ultrasound can predict the risk of surgery in Crohn's disease: Proposal of an ultrasonographic score. Scandinavian Journal of Gastroenterology, 2009, 44, 585-593.	0.6	72
11	Adalimumab in active ulcerative colitis: A "real-life―observational study. Digestive and Liver Disease, 2013, 45, 738-743.	0.4	72
12	Prevalence of celiac disease in inflammatory bowel diseases: An IG-IBD multicentre study. Digestive and Liver Disease, 2010, 42, 175-178.	0.4	70
13	Pregnancy before and after the diagnosis of inflammatory bowel diseases: Retrospective case?control study. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 542-549.	1.4	68
14	Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerativeÂcolitis. Gastrointestinal Endoscopy, 2017, 86, 1118-1127.e5.	0.5	62
15	Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. Journal of Crohn's and Colitis, 2014, 8, 852-858.	0.6	54
16	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Digestive and Liver Disease, 2017, 49, 604-617.	0.4	47
17	EUS diagnosis and simultaneous endoscopic retrograde cholangiography treatment of common bile duct stones by using an oblique-viewing echoendoscope. Gastrointestinal Endoscopy, 2006, 63, 479-484.	0.5	44
18	Advances in biologic therapy for ulcerative colitis and Crohn's disease. Current Gastroenterology Reports, 2006, 8, 506-512.	1.1	43

#	Article	IF	CITATIONS
19	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2017, 49, 338-358.	0.4	42
20	Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 294-306.	3.7	42
21	Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. European Journal of Pharmaceutical Sciences, 2010, 39, 428-436.	1.9	41
22	Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study. Inflammatory Bowel Diseases, 2011, 17, 758-766.	0.9	41
23	An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis. Gastroenterology, 2021, 160, 1558-1569.e8.	0.6	41
24	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. Digestive and Liver Disease, 2014, 46, 963-968.	0.4	39
25	CARD15 Gene Variants and Risk of Reoperation in Crohn's Disease Patients. American Journal of Gastroenterology, 2009, 104, 2483-2491.	0.2	37
26	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2019, 51, 632-639.	0.4	36
27	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Digestive and Liver Disease, 2016, 48, 360-370.	0.4	34
28	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case–Control IG-IBD Study. Inflammatory Bowel Diseases, 2019, 26, 450-459.	0.9	33
29	Interassay and Interobserver Variability in the Detection of Anti-neutrophil Cytoplasmic Antibodies in Patients with Ulcerative Colitis. Clinical Chemistry, 2004, 50, 1422-1425.	1.5	32
30	Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polyps. Endoscopy, 2018, 50, 779-789.	1.0	32
31	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. Journal of Crohn's and Colitis, 2016, 10, 913-924.	0.6	30
32	Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study. Journal of Crohn's and Colitis, 2014, 8, 1642-1652.	0.6	27
33	Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. Journal of Crohn's and Colitis, 2016, 11, jjw181.	0.6	27
34	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Digestive and Liver Disease, 2019, 51, 972-977.	0.4	25
35	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the <scp>IGâ€IBD LIVE</scp> study. Alimentary Pharmacology and Therapeutics, 2022, 56, 95-109.	1.9	25
36	Ustekinumab in the management of Crohn's disease: Expert opinion. Digestive and Liver Disease, 2018, 50, 653-660.	0.4	22

#	Article	IF	CITATIONS
37	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease, 2022, 54, 440-451.	0.4	22
38	The prevalence of hyper- and hypothyroidism in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2008, 2, 327-330.	0.6	18
39	Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. Digestive and Liver Disease, 2016, 48, 138-143.	0.4	18
40	Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). Gut, 2022, 71, 1078-1087.	6.1	18
41	Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. Gut, 2021, 70, gutjnl-2020-320690.	6.1	17
42	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. Advances in Therapy, 2018, 35, 545-562.	1.3	16
43	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. United European Gastroenterology Journal, 2020, 8, 1228-1235.	1.6	16
44	PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis. United European Gastroenterology Journal, 2022, 10, 147-159.	1.6	16
45	The diagnosis of inflammatory bowel disease is often unsupported in clinical practice. Digestive and Liver Disease, 2015, 47, 20-23.	0.4	12
46	Eosinophilia – associated basal plasmacytosis: an early and sensitive histologic feature of inflammatory bowel disease. Apmis, 2017, 125, 179-183.	0.9	12
47	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterology Research and Practice, 2019, 2019, 1-9.	0.7	12
48	Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohns Disease: Tipping the Balance. Current Medicinal Chemistry, 2007, 14, 1489-1497.	1.2	11
49	Treatment of tracheoesophageal fistula in a child by using an endoscopic suturing device. Gastrointestinal Endoscopy, 2007, 65, 932-935.	0.5	11
50	Identification of a new WASP and FKBP-like (WAFL) protein in inflammatory bowel disease: a potential marker gene for ulcerative colitis. International Journal of Colorectal Disease, 2008, 23, 921-930.	1.0	11
51	Ustekinumab for treating ulcerative colitis: an expert opinion. Expert Opinion on Biological Therapy, 2020, 20, 1321-1329.	1.4	11
52	Impact of various central endoscopy reading models on treatment outcome in Crohn's disease using data from the randomized, controlled, exploratory cohort arm of the BERGAMOT trial. Gastrointestinal Endoscopy, 2021, 93, 174-182.e2.	0.5	11
53	Lower gastrointestinal bleeding in Crohn's disease: How (un-)common is it and how to tackle it?. Digestive and Liver Disease, 2012, 44, 721-722.	0.4	10
54	Twoâ€year effectiveness and safety of golimumab in ulcerative colitis: An IGâ€IBD study. United European Gastroenterology Journal, 2021, 9, 102-109.	1.6	8

#	Article	IF	CITATIONS
55	Topical Therapy in Ulcerative Colitis: Always a Bridesmaid but Never a Bride?. Gastroenterology, 2015, 148, 701-704.	0.6	7
56	Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study. Digestive and Liver Disease, 2017, 49, 997-1002.	0.4	7
57	Asymptotic distributions of kappa statistics and their differences with many raters, many rating categories and two conditions. Biometrical Journal, 2018, 60, 146-154.	0.6	7
58	Predictivity of early and late assessment for post-surgical recurrence of Crohn's disease: Data from a single-center retrospective series. Digestive and Liver Disease, 2021, 53, 987-995.	0.4	7
59	Unmet needs of Italian physicians managing patients with inflammatory bowel disease. Digestive and Liver Disease, 2019, 51, 212-217.	0.4	6
60	Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. Journal of Crohn's and Colitis, 2022, 16, 1011-1019.	0.6	6
61	Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation. Digestive and Liver Disease, 2019, 51, 1117-1122.	0.4	5
62	Genotype–phenotype relationship in inflammatory bowel disease. European Journal of Internal Medicine, 2000, 11, 204-209.	1.0	4
63	Barriers to antiâ€∢NFalpha prescription among Italian physicians managing inflammatory bowel disease. GastroHep, 2019, 1, 93-99.	0.3	3
64	Has the Removing of the Mesentery during Ileo-Colic Resection an Impact on Post-Operative Complications and Recurrence in Crohn's Disease? Results from the Resection of the Mesentery Study (Remedy). Journal of Clinical Medicine, 2022, 11, 1961.	1.0	3
65	Advances in medical therapy for Crohn's disease. Current Gastroenterology Reports, 2002, 4, 506-512.	1.1	2
66	Post-operative Recurrence of Crohn's Disease: There Is More to It than Meets the Eye. Journal of Crohn's and Colitis, 2016, 10, 999-1000.	0.6	2
67	Risk factors of <scp>SARSâ€CoV</scp> â€2 seroprevalence among hospital employees in Italy: a singleâ€centre study. Internal Medicine Journal, 2021, 51, 1049-1059.	0.5	2
68	Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. European Journal of Gastroenterology and Hepatology, 2021, 33, 1082-1090.	0.8	2
69	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Digestive and Liver Disease, 2021, , .	0.4	2
70	Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD). Digestive and Liver Disease, 2020, 52, 928-930.	0.4	1
71	Scoring Endoscopy in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 48-53.	0.9	1
72	Rescue immune suppression for severe colitis—worth the risk?. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 303-304.	8.2	0

#	Article	IF	CITATIONS
73	Internal radiation by 131-iodine lipiodol in unresectable hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 962-963.	0.4	0